Shiwa Mieko, Nishimura Yumiko, Wakatabe Rumi, Fukawa Ai, Arikuni Hisashi, Ota Hiroyuki, Kato Yo, Yamori Takao
Yokohama Laboratory, Ciphergen Biosystems K.K., Yokohama Business Park East Tower 14F, 134 Godo-cho, Hodogaya-ku, Yokohama, Kanagawa, Japan.
Biochem Biophys Res Commun. 2003 Sep 12;309(1):18-25. doi: 10.1016/s0006-291x(03)01520-1.
Useful biomarkers are needed for early detection of cancers. To demonstrate the potential diagnostic usefulness of a new proteomic technology, we performed Expression Difference Mapping analysis on 39 cancer cell lines from 9 different tissues using ProteinChip technology. A protein biomarker candidate of 12kDa was found in colon cancer cells. We then optimized the purification conditions for this biomarker by utilizing Retentate Chromatography mass spectrometry (RC-MS). The optimized purification conditions developed "on-chip" were directly transferred to conventional chromatography to purify the biomarker, which was identified as prothymosin-alpha by ProteinChip time-of-flight mass spectrometry (TOF MS) and ProteinChip-Tandem MS systems. The relative expression level of prothymosin-alpha between colon cancer cells and normal colon mucosal cells was evaluated on the same ProteinChip platform. Prothymosin-alpha expression in colon cancer cells was clearly higher than in normal colon cells. These results indicate that prothymosin-alpha could be a potential biomarker for colon cancer, and that the ProteinChip platform could perform the whole process of biomarker discovery from screening to evaluation of the identified marker.